10/28/2026
👥 Designed for today's obesity care team.
Whether you practice in obesity medicine, endocrinology, primary care, cardiometabolic medicine, or pharmacy, this activity provides practical, evidence-based insights into the evolving role of amylin.
👉 https://cmeo.me/SN-315
Obesity care is moving quickly past the one-drug, one-pathway era. Current therapies have reshaped what treatment can achieve, yet responses vary widely and not every patient tolerates or responds to them, leaving clinicians searching for the...